Retinal Disease and Neovascular Age-related Macular Degeneration
Opthea Limited’s clinical research is centered on neovascular age-related macular degeneration (wet AMD), with studies focused on vision-threatening retinal disease and the treatment of abnormal blood vessel growth in the macula.
- Wet AMD
- Neovascular macular disease
The sponsor’s trials examine treatment strategies for patients with active retinal vascular disease in multiple international sites.
Anti-VEGF Combination Therapy
The research portfolio includes combination approaches pairing OPT-302 with established anti-VEGF therapies, reflecting a therapeutic interest in enhancing management of choroidal neovascularization in wet AMD.
- OPT-302
- Aflibercept
- Ranibizumab
These studies are directed toward improving outcomes in patients receiving intravitreal treatment for macular degeneration.
Ophthalmology and Visual Function
Opthea’s clinical activity is firmly within ophthalmology, with a therapeutic emphasis on preserving vision in people affected by degenerative retinal conditions.
- Retinal specialist care
- Macular edema
- Central vision loss
The sponsor’s research sites span multiple countries, supporting study access for patients with advanced ocular disease.
